I unfortunately agree at this point. The time to have been scooped up on a big-pharma-friendly deal would have been months ago. RGBP is now in developmental mode, trying to partner with another company and get some clinical trials up and going. I think at this point big pharma is going to want to see some proof of concept before forking over any cash. RGBP is going to have to come up with a formula and show that it works. If the deal with Canary goes through, and Canary can provide the testing products to determine if a person has the right type of cancer for RGBP's formula, then the total value of Regen/Canary is even more. I estimated about $8-$10 billion for Regent's patents. But if they can prove their concept and also have the testing product to determine who should be treated with their drug, then I place their value at a minimum of $30 billion, with a maximum of whatever the buying and selling parties can negotiate -- could be in the $70-$100 billion range. Not even kidding. Cancer is big money.
News 
Market Data 
Discover 
AI
